Last reviewed · How we verify
NCT05552521: SepticHeartG
Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
trial testing Echocardiography in Diastolic Dysfunction in 100 participants. Completed in 26 February 2024.
26 February 2024
Quick facts
| Lead sponsor | Hospital Garcia de Orta |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 20 September 2022 |
| Primary completion | 26 February 2024 |
| Estimated completion | 26 February 2024 |
| Sites | 1 location across Portugal |
Drugs / interventions tested
- Echocardiography
Conditions studied
- Diastolic Dysfunction — all drugs for Diastolic Dysfunction →
- Septic Shock — all drugs for Septic Shock →
- Cardiomyopathies — all drugs for Cardiomyopathies →
Sponsor
Hospital Garcia de Orta
Who can join
18 and older, any sex, with Diastolic Dysfunction or Septic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sepsis is a life-threatening infection with increasing incidence, and its spectrum of disease can involve cardiac dysfunction, which further adds to mortality. Although cardiac involvement in sepsis has been classically attributed to systolic dysfunction, diastolic dysfunction is increasingly diagnosed due to new echocardiographic techniques and the conceptual evolution of diastolic dysfunction. Combining systolic and diastolic dysfunction assessment could lead to a better diagnosis of septic cardiac dysfunction. Furthermore, earlier forms of septic cardiac dysfunction could be more promptly recognized by measuring novel and less used parameters of diastolic dysfunction. We hypothesize that left atrium (LA) strain and isovolumetric relaxation time (IVRT) derived intervals could be new and earlier predictors of diastolic dysfunction in septic patients with a potential impact on clinical presentation and prognosis and that rare genetic variation associated with inherited cardiomyopathies could underline the risk and severity of sepsis-related myocardial dysfunction with potential impact on diagnosis and prognosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Sepsis-induced myocardial dysfunction diagnosed with strain versus non-strain echocardiography parameters: incidence, evolution and association with prognosis.
Gonzalez FA, Bacariza J, Varudo AR, Leote J, et al · · 2025 · cited 1× · PMID 40999250 · DOI 10.1186/s13613-025-01561-w
Verify or expand the search:
- PubMed search for NCT05552521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Echocardiography
Trials testing the same drug.
- NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
- NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
- NCT06434064 — Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advan · Phase 2 · recruiting
- NCT06871410 — Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
Other recruiting trials for Diastolic Dysfunction
Currently open trials in the same condition.
- NCT06584734 — Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients · NA · active not recruiting
- NCT05408559 — Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES · Phase 1, PHASE2 · recruiting
- NCT03972644 — Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis · NA · recruiting
Other Hospital Garcia de Orta trials
Trials by the same sponsor.
- NCT05336448 — POCUS AI in Critically Ill Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05552521 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Garcia de Orta
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05552521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing